166 related articles for article (PubMed ID: 33180981)
1. Simplified Monopalmitoyl Toll-like Receptor 2 Ligand Mini-UPam for Self-Adjuvanting Neoantigen-Based Synthetic Cancer Vaccines.
van den Ende TC; Heuts JMM; Gential GPP; Visser M; van de Graaff MJ; Ho NI; Jiskoot W; Valentijn ARPM; Meeuwenoord NJ; Overkleeft HS; Codée JDC; van der Burg SH; Verdegaal EME; van der Marel GA; Ossendorp F; Filippov DV
Chembiochem; 2021 Apr; 22(7):1215-1222. PubMed ID: 33180981
[TBL] [Abstract][Full Text] [Related]
2. N-tetradecylcarbamyl lipopeptides as novel agonists for Toll-like receptor 2.
Willems MM; Zom GG; Khan S; Meeuwenoord N; Melief CJ; van der Stelt M; Overkleeft HS; Codée JD; van der Marel GA; Ossendorp F; Filippov DV
J Med Chem; 2014 Aug; 57(15):6873-8. PubMed ID: 25019313
[TBL] [Abstract][Full Text] [Related]
3. Efficient induction of antitumor immunity by synthetic toll-like receptor ligand-peptide conjugates.
Zom GG; Khan S; Britten CM; Sommandas V; Camps MG; Loof NM; Budden CF; Meeuwenoord NJ; Filippov DV; van der Marel GA; Overkleeft HS; Melief CJ; Ossendorp F
Cancer Immunol Res; 2014 Aug; 2(8):756-64. PubMed ID: 24950688
[TBL] [Abstract][Full Text] [Related]
4. Self-adjuvanting vaccine against group A streptococcus: application of fibrillized peptide and immunostimulatory lipid as adjuvant.
Azmi F; Ahmad Fuaad AA; Giddam AK; Batzloff MR; Good MF; Skwarczynski M; Toth I
Bioorg Med Chem; 2014 Nov; 22(22):6401-8. PubMed ID: 25438764
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Lipopeptides as Toll-like Receptor 2 Ligands.
Hussein WM; Choi PM; Zhang C; Su M; Sierecki E; Johnston W; Fagan V; Alexandrov K; Skwarczynski M; Gambin Y; Toth I; Simerska P
Curr Drug Deliv; 2017; 14(7):935-943. PubMed ID: 27494158
[TBL] [Abstract][Full Text] [Related]
6. Self-Adjuvanting Cancer Vaccines from Conjugation-Ready Lipid A Analogues and Synthetic Long Peptides.
Reintjens NRM; Tondini E; de Jong AR; Meeuwenoord NJ; Chiodo F; Peterse E; Overkleeft HS; Filippov DV; van der Marel GA; Ossendorp F; Codée JDC
J Med Chem; 2020 Oct; 63(20):11691-11706. PubMed ID: 32960056
[TBL] [Abstract][Full Text] [Related]
7. Design of fully synthetic, self-adjuvanting vaccine incorporating the tumor-associated carbohydrate Tn antigen and lipoamino acid-based Toll-like receptor 2 ligand.
Abdel-Aal AB; El-Naggar D; Zaman M; Batzloff M; Toth I
J Med Chem; 2012 Aug; 55(15):6968-74. PubMed ID: 22800462
[TBL] [Abstract][Full Text] [Related]
8. Development of a vaccine based on bacteria-mimicking tumor cells coated with novel engineered toll-like receptor 2 ligands.
Akazawa T; Ohashi T; Wijewardana V; Sugiura K; Inoue N
Cancer Sci; 2018 May; 109(5):1319-1329. PubMed ID: 29575556
[TBL] [Abstract][Full Text] [Related]
9. Immune and anticancer responses elicited by fully synthetic aberrantly glycosylated MUC1 tripartite vaccines modified by a TLR2 or TLR9 agonist.
Abdel-Aal AB; Lakshminarayanan V; Thompson P; Supekar N; Bradley JM; Wolfert MA; Cohen PA; Gendler SJ; Boons GJ
Chembiochem; 2014 Jul; 15(10):1508-13. PubMed ID: 24890740
[TBL] [Abstract][Full Text] [Related]
10. Simple synthetic toll-like receptor 2 ligands.
Abdel-Aal AB; Al-Isae K; Zaman M; Toth I
Bioorg Med Chem Lett; 2011 Oct; 21(19):5863-5. PubMed ID: 21855334
[TBL] [Abstract][Full Text] [Related]
11. Peptides conjugated to 2-alkoxy-8-oxo-adenine as potential synthetic vaccines triggering TLR7.
Gential GPP; Hogervorst TP; Tondini E; van de Graaff MJ; Overkleeft HS; Codée JDC; van der Marel GA; Ossendorp F; Filippov DV
Bioorg Med Chem Lett; 2019 Jun; 29(11):1340-1344. PubMed ID: 30952595
[TBL] [Abstract][Full Text] [Related]
12. Chirality of TLR-2 ligand Pam3CysSK4 in fully synthetic peptide conjugates critically influences the induction of specific CD8+ T-cells.
Khan S; Weterings JJ; Britten CM; de Jong AR; Graafland D; Melief CJ; van der Burg SH; van der Marel G; Overkleeft HS; Filippov DV; Ossendorp F
Mol Immunol; 2009 Mar; 46(6):1084-91. PubMed ID: 19027958
[TBL] [Abstract][Full Text] [Related]
13. Novel TLR2-binding adjuvant induces enhanced T cell responses and tumor eradication.
Zom GG; Willems MMJHP; Khan S; van der Sluis TC; Kleinovink JW; Camps MGM; van der Marel GA; Filippov DV; Melief CJM; Ossendorp F
J Immunother Cancer; 2018 Dec; 6(1):146. PubMed ID: 30541631
[TBL] [Abstract][Full Text] [Related]
14. A Self-Adjuvanting Vaccine Platform: Optimization of Site-Specific Sortase A Mediated Conjugation of Toll-Like Receptor 2 Ligands onto the Carboxyl or Amino terminus of Recombinant Protein Antigens.
Xu Z; Moyle PM
Chempluschem; 2020 Jan; 85(1):227-236. PubMed ID: 31944609
[TBL] [Abstract][Full Text] [Related]
15. Towards a fully synthetic MUC1-based anticancer vaccine: efficient conjugation of glycopeptides with mono-, di-, and tetravalent lipopeptides using click chemistry.
Cai H; Huang ZH; Shi L; Zhao YF; Kunz H; Li YM
Chemistry; 2011 May; 17(23):6396-406. PubMed ID: 21538615
[TBL] [Abstract][Full Text] [Related]
16. Enhanced immunostimulatory activity of in silico discovered agonists of Toll-like receptor 2 (TLR2).
Murgueitio MS; Ebner S; Hörtnagl P; Rakers C; Bruckner R; Henneke P; Wolber G; Santos-Sierra S
Biochim Biophys Acta Gen Subj; 2017 Nov; 1861(11 Pt A):2680-2689. PubMed ID: 28734965
[TBL] [Abstract][Full Text] [Related]
17. Targeting self and neo-epitopes with a modular self-adjuvanting cancer vaccine.
Belnoue E; Mayol JF; Carboni S; Di Berardino Besson W; Dupuychaffray E; Nelde A; Stevanovic S; Santiago-Raber ML; Walker PR; Derouazi M
JCI Insight; 2019 Apr; 5(11):. PubMed ID: 31013258
[TBL] [Abstract][Full Text] [Related]
18. Fully synthetic self-adjuvanting thioether-conjugated glycopeptide-lipopeptide antitumor vaccines for the induction of complement-dependent cytotoxicity against tumor cells.
Cai H; Sun ZY; Huang ZH; Shi L; Zhao YF; Kunz H; Li YM
Chemistry; 2013 Feb; 19(6):1962-70. PubMed ID: 23280874
[TBL] [Abstract][Full Text] [Related]
19. Modular platforms for the assembly of self-adjuvanting lipopeptide-based vaccines for use in an out-bred population.
Zeng W; Horrocks KJ; Tan ACL; Wong CY; Chua BY; Jackson DC
Vaccine; 2020 Jan; 38(3):597-607. PubMed ID: 31740096
[TBL] [Abstract][Full Text] [Related]
20. TLR2 ligand-synthetic long peptide conjugates effectively stimulate tumor-draining lymph node T cells of cervical cancer patients.
Zom GG; Welters MJ; Loof NM; Goedemans R; Lougheed S; Valentijn RR; Zandvliet ML; Meeuwenoord NJ; Melief CJ; de Gruijl TD; Van der Marel GA; Filippov DV; Ossendorp F; Van der Burg SH
Oncotarget; 2016 Oct; 7(41):67087-67100. PubMed ID: 27564262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
